AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Osborne, C. S.
Right arrow Articles by Ryder, N. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Osborne, C. S.
Right arrow Articles by Ryder, N. S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2003, p. 3634-3636, Vol. 47, No. 11
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.11.3634-3636.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

In Vitro Analysis of the Ability of Trichophyton rubrum To Become Resistant to Terbinafine

Colin S. Osborne,* Bettina Hofbauer, Bertrand Favre,{dagger} and Neil S. Ryder{ddagger}

Novartis Research Institute, 1235 Vienna, Austria

Received 14 April 2003/ Returned for modification 2 June 2003/ Accepted 15 August 2003

In this study, we have investigated in vitro the resistance frequency and development of resistance to terbinafine of Trichophyton rubrum. Results demonstrated that naturally occurring mutants are rare and that T. rubrum appears to have little capacity to develop resistance to terbinafine even after prolonged exposure.

* Corresponding author. Present address: Infectious Diseases Biology, Room 8654, Novartis Institutes for BioMedical Research, Inc., 100 Technology Sq., Cambridge, MA 02139. Phone: (617) 871-3142. Fax: (617) 871-7058. E-mail: colin.osborne{at}pharma.novartis.com.

{dagger} Present address: Department of Dermatology, University Hospital CHUV, 1011 Lausanne, Switzerland.

{ddagger} Present address: Novartis Institutes for Biomedical Research, Inc., Cambridge, MA 02139.

Antimicrobial Agents and Chemotherapy, November 2003, p. 3634-3636, Vol. 47, No. 11
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.11.3634-3636.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2003 by the American Society for Microbiology. All rights reserved.